Clinical Trial Update: Berodual® Respimat® vs Metered Dose Inhaler in Patients With Chronic Obstructive Pulmonary Disease [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing Berodual Respimat with a Metered Dose Inhaler in chronic obstructive pulmonary disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Berodual Respimat (ipratropium bromide and fenoterol hydrobromide)
• Metered Dose Inhaler

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 3 | Status: TERMINATED